Author Archives: Lu Rahman

#Flow Cytometry

Bio-Rad launches three StarBright Dyes for flow cytometry

Bio-Rad Laboratories has launched three StarBright Dyes specifically developed for flow cytometry. StarBright Blue 700, StarBright Violet 440, and StarBright Violet 610 are fluorescent nanoparticles that are conjugated to Bio-Rad’s highly validated flow antibodies, providing maximal brightness and improved resolution. Brighter than other fluorescent dyes with similar excitation and emission… Read More

#News

#Pharmaceutical #Sustainability

GSK sets environmental goals of zero impact on climate by 2030

GSK has announced ambitious new environmental sustainability goals in both climate and nature, aiming to have a net zero impact on climate and a net positive impact on nature by 2030. The new goals form part of GSK’s Trust priority and ESG approach, which support the company’s aim to create… Read More

#News

#Antibodies #Covid-19

Method finds COVID-19 monoclonal antibody among a trillion possibilities

University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralising human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. The method– as well as a trio of successful animal studies on an antibody called ‘Ab1’– are described today in the Proceedings of the… Read More

#Covid-19 #News

#Autoimmune disease #Drug candidates #Drug discovery

Beetroot peptide potential drug candidate for neurodegenerative and inflammatory diseases

In a recent study, a research group led by Christian Gruber at MedUni Vienna’s Institute of Pharmacology isolated a peptide (small protein molecule) from beetroot. The peptide is able to inhibit a particular enzyme that is responsible for the breakdown of messenger molecules in the body. Due to its particularly… Read More

#Editor's Choice #News

#Drug candidates #Live bio therapeutics #Pharmaceutical

4D pharma merger with Longevity to gain NASDAQ listing

4D pharma, a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome – and Longevity Acquisition a NASDAQ-listed Special Purpose Acquisition Company (SPAC), have announced a proposed merger. The deal is worth up to $37.6 million to 4D pharma. Read More

#News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Analysis shows difference of up to three months in current COVID-19 vaccine trial recruitment

Analysis from virtual clinical development specialist Phesi shows the enrolment and effectiveness of two current COVID-19 vaccine trials conducted by global pharmaceutical development companies. On the surface, both trials appear to be on track to complete enrolment, however, looking deeper, there is a significant difference in the Site Effectiveness Index… Read More

#Covid-19 #News

#Assay development optimisation & technology #Drug discovery #High Content Screening #RNA

PerkinElmer to acquire Horizon Discovery for $383 million

PerkinElmer will acquire Horizon Discovery for approximately $383 million (£296 million). The transaction is expected to close in the first quarter of 2021 subject to conditions. The investment will allow PerkinElmer to expand its portfolio of leading, automated life sciences discovery and applied genomics solutions to include gene editing and… Read More

#News #Trending News

#Drug discovery #Novel candidates

Tube-dwelling anemone toxins have pharmacological potential

By André Julião, Agência FAPESP Researchers based in Brazil and the US have completed the first-ever mapping exercise to profile the toxins produced by tube-dwelling anemones, or cerianthids, a family of marine animals belonging to the same phylum (Cnidaria) as sea anemones, jellyfish and corals. The analysis revealed that the… Read More

#Editor's Choice #News

#Assay development & optimisation

PROTAC assays: successfully measuring protein degradation

PROTAC (PROteolysis TArgeting Chimera) is one of the hottest topics in drug discovery today as it is a highly promising new approach to targeted therapy. It offers several advantages over traditional occupancy-based drugs, with a potential to target the ‘undruggable’ proteome. Payash Bahuguna, Aurelia Bioscience explains more about PROTAC and… Read More

#News

#Cancer research #Immunotherapy

Scientists engineer new cancer immunotherapy to train immune system in cancer fight

A new type of cancer immunotherapy developed at the Icahn School of Medicine at Mount Sinai trains the innate immune system to help it eliminate tumour cells through the use of nanobiologics, tiny materials bioengineered from natural molecules that are paired with a therapeutic component, according to a study published… Read More

#Cancer Research #News #Trending News

#Cancer research #Oncology

Cancer Research UK collaboration will identify oncology innovation

The national programme, to develop and progress start-up oncology projects, is being launched by Bruntwood SciTech at Alderley Park with funding from Innovate UK and Cancer Research UK A collaboration of global pharmaceutical and healthcare companies, research institutions and public bodies will identify oncology innovations and leverage their combined insight… Read More

#Cancer Research #Editor's Choice #News

#Biomarkers #Covid-19 #Metabolomics

Study identifies biomarkers that could be used in a quick, inexpensive COVID-19 screening tool

A new study from Lawson Health Research Institute, Western University and University of Alberta suggests that COVID-19 affects the human body’s blood concentration levels of specific metabolites – small molecules broken down in the human body through the process of metabolism. Three specific metabolites identified in this study could act… Read More

#Covid-19 #News

Lab software improves user experience and increases efficiency

H.E.L Group, developer and manufacturer of innovative laboratory tools has released laboratory automation software labCONSOL, designed to support customers in the automation and coordination of laboratory equipment. The software, which builds on the company’s proven WinISO technology, has a new and intuitive user interface, and provides a scalable platform for… Read More

#News

#Cancer #Oncology #Precision medicine

Mission Bio launches single-cell multi-omics system for precision cancer therapies

Mission Bio has launched the Tapestri Single-cell Multi-omics Solution – a comprehensive single-cell multi-omics platform. With a new instrument, single-cell multi-omics reagent kits, TotalSeq-D antibody content from BioLegend, and visualisation software, the package provides layered insight into multiple analytes across all blood cancers, reducing drug development time and cost by… Read More

#Cancer Research #News

#AI / data analytics / healthtech / informatics #Clinical trials

New digital platform assists with clinical trial organisation

Wirano is a new digital platform to help with rapid and effective organisation of clinical trials. The platform aims to revolutionise the activities involved in clinical trials by accelerating start-up of trials, optimising patient recruitment, and improving site and investigator selection processes. “The enormous cost of clinical trials in terms… Read More

#News